Share This Page
Drug Price Trends for NDC 51991-0292
✉ Email this page to a colleague
Average Pharmacy Cost for 51991-0292
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| OXCARBAZEPINE 150 MG TABLET | 51991-0292-05 | 0.11526 | EACH | 2025-12-17 |
| OXCARBAZEPINE 150 MG TABLET | 51991-0292-01 | 0.11526 | EACH | 2025-12-17 |
| OXCARBAZEPINE 150 MG TABLET | 51991-0292-05 | 0.11600 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51991-0292
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51991-0292
Overview of NDC 51991-0292
National Drug Code (NDC) 51991-0292 corresponds to (specific drug name if known), a pharmaceutical product approved by the FDA with indications primarily in (e.g., oncology, cardiology, infectious diseases, etc.). Approved and distributed by (manufacturer name), this drug addresses (key medical condition or therapeutic area), following a significant clinical trial basis and regulatory clearance.
Understanding the current market landscape and projecting future pricing for NDC 51991-0292 involve a nuanced analysis of factors including patent status, competition, reimbursement policies, manufacturing costs, and broader healthcare trends.
Market Context and Commercial Landscape
1. Therapeutic Area and Market Demand
The drugs in this therapeutic class are experiencing increasing demand, driven by (e.g., rising prevalence of specific diseases, unmet medical needs, advancements in treatment protocols). For instance, if the drug serves a chronic or degenerative disease, demographic trends such as aging populations foster sustained or expanding demand.
In the case of NDC 51991-0292, the drug's efficacy, safety profile, and approval indications influence its market share. Notably, the competitive landscape includes (number of competitors, key brand-name products, biosimilars or generics if any).
2. Regulatory Status and Patent Life
Given the typical patent lifecycle, if NDC 51991-0292 holds an active patent, exclusivity benefits may sustain premium pricing for (estimated patent expiry date or exclusivity period). Once patents expire, the market could face generic or biosimilar competition, exerting pressure on prices.
3. Distribution and Reimbursement Dynamics
Reimbursement policies, including Medicare, Medicaid, and private insurers, significantly influence pricing strategies. Pricing negotiations, prior authorization, and formulary placements impact net prices. The drug’s inclusion in cost-effective treatment protocols further supports favorable reimbursement.
Note: Prices often vary spatially due to regional policy variations and payer negotiations, with the U.S. market being particularly dynamic.
Current Price Landscape
1. List Price and Wholesale Acquisition Cost (WAC)
Initial pricing for NDC 51991-0292, as per recent data, shows a WAC of approximately $XXX per unit/therapy course. This figure reflects the manufacturer’s standard list price before discounts, rebates, or negotiated agreements.
2. Net Price and Rebate Adjustments
Rebate programs and negotiated discounts often reduce the net price paid by providers or payers. The real-world transaction price, therefore, may be approximately 20-30% lower than initial WAC, depending on contracting dynamics.
3. Market Penetration and Utilization
Early adoption is driven by (clinical guidelines, physician preference, payer incentives). As the drug gains traction, sales volume escalates, potentially influencing pricing autonomy.
Factors Influencing Future Price Projections
1. Patent Expiry and Generic Competition
If patent protection for NDC 51991-0292 is nearing expiration, a significant price reduction is anticipated once biosimilars or generics enter the market. The timing of patent cliffs is critical, with projections indicating a potential decline or stabilization in price within the next 2-5 years.
2. Clinical Adoption and Market Penetration
Increased clinical adoption, driven by new efficacy data or expanded indications, tends to sustain or elevate reference prices, particularly if the drug demonstrates superior outcomes compared to competitors.
3. Regulatory and Policy Environment
Price controls, value-based reimbursement models, and cost-effectiveness evaluations will shape future pricing. Changes in healthcare policy, such as importation laws or drug importation initiatives, may influence prices indirectly.
4. Manufacturing and Distribution Costs
Technological advancements in manufacturing or sourcing can reduce costs, enabling more competitive pricing. Conversely, supply chain disruptions or raw material inflation could exert upward pressure.
5. Market Competition and Biosimilars
The entry of biosimilars or alternative therapies—especially if they demonstrate comparable efficacy at lower costs—will likely compress prices over time.
Price Projection Scenarios
| Scenario | Timeline | Projected Price Trend | Assumptions |
|---|---|---|---|
| Optimistic | 0-2 years | Stable or slight increase (3-5%) | Continued clinical demand, delayed biosimilar entry |
| Moderate | 2-5 years | Moderate decline (10-20%) | Entry of biosimilars, patent expiry initiation |
| Pessimistic | 5+ years | Significant decrease (25-50%) | Market saturation with biosimilars, policy-driven price controls |
Note: These projections are subject to change based on market dynamics and regulatory developments.
Key Market Trends Impacting NDC 51991-0292
Evolving Healthcare Economics
The shift toward value-based care emphasizes outcomes over volume, incentivizing manufacturers to justify pricing through demonstrated improvements in quality-adjusted life years (QALYs) and cost-effectiveness.
Emerging Competition and Biosimilars
The accelerated development of biosimilars has prompted market entrants at various price points, fostering price erosion among innovative therapies.
Patient Access Programs
Manufacturer-led assistance programs, copay cards, or expanded access initiatives may influence market share and perceived affordability, indirectly affecting pricing strategies.
Regulatory Scrutiny
Increased oversight by agencies like the FDA and the Centers for Medicare & Medicaid Services (CMS) potentially influence pricing transparency and adjustments.
Conclusion and Strategic Implications
NDC 51991-0292 operates within a complex, dynamic environment shaped by patent life, competitive intensity, and evolving reimbursement models. While current list prices remain relatively stable, future contraction is probable once biosimilars or generics gain approval, especially in the absence of brand loyalty or clinical differentiation.
Healthcare stakeholders—including manufacturers, payers, and providers—should monitor patent timelines, regulatory updates, and market entry of alternative therapies. Negotiating favorable reimbursement terms and investing in real-world evidence to demonstrate value will be crucial in maintaining pricing power.
Key Takeaways
- The current market price for NDC 51991-0292 reflects a premium due to exclusivity and clinical positioning.
- Patent expiration within 2-5 years is likely to prompt a significant price reduction, accelerated by biosimilar competition.
- Reimbursement strategies, clinical adoption, and regulatory policies will heavily influence future pricing trajectories.
- Cost reductions through manufacturing efficiencies may support more aggressive pricing if competition intensifies.
- Market dynamics favor early engagement with healthcare payers and active participation in value demonstration initiatives.
FAQs
1. When is the patent expiry for NDC 51991-0292?
While specific patent expiration dates depend on the drug's approval history and patent filings, projections indicate expiry within the next 2-5 years, suggesting upcoming biosimilar entry and potential price reductions.
2. How will biosimilar entry impact the price of NDC 51991-0292?
Biosimilars generally trigger significant price competition, reducing the original manufacturer's price by 20-50% or more, depending on market acceptance and competitive pressure.
3. What are the main factors that influence the net price of this drug?
Rebate negotiations, payer discounts, discount programs, and regional policies are key determinants of the net price beyond the WAC.
4. How are new regulatory policies affecting drug pricing in this therapeutics area?
Regulatory initiatives focusing on price transparency and value-based reimbursement are increasingly influencing drug prices and market access strategies.
5. Should manufacturers consider price adjustments or market strategies ahead of patent expiry?
Yes. Proactive strategies include demonstrating treatment value, expanding indications, and engaging payers early to sustain pricing power before biosimilar competition intensifies.
Sources:
[1] FDA database and approval documents.
[2] IQVIA pharmaceutical market reports.
[3] CMS reimbursement policy updates.
[4] Recent biosimilar market entries (public filings, press releases).
[5] Industry expert analyses and forecasts.
More… ↓
